Non-invasive detection of neurochemical changes prior to overt pathology in a mouse model of spinocerebellar ataxia type 1

Journal of Neurochemistry

Volumn 127, Issue 5, 2013, Pages 660-668

  Emir, Uzay E ^a,d   Brent Clark, Howard ^b   Vollmers, Manda L ^a   Eberly, Lynn E ^c   Öz, Gülin ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cerebellum; histology; magnetic resonance spectroscopy; mouse model; neurodegeneration; SCA1

Indexed keywords

BRAIN PROTEIN; CHOLINE; CREATINE; GLUTAMINE; SCA1 154Q; SCA1 2Q; TAURINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HISTOPATHOLOGY; MALE; MOUSE; NEUROCHEMISTRY; NEUROPATHOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR DEGENERATION; WILD TYPE;

MUS; MUS MUSCULUS;

CEREBELLUM; HISTOLOGY; MAGNETIC RESONANCE SPECTROSCOPY; MOUSE MODEL; NEURODEGENERATION; SCA1;

ANIMALS; CEREBELLUM; CHOLINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE KNOCK-IN TECHNIQUES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, MUTANT STRAINS; NERVE DEGENERATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; SPINOCEREBELLAR ATAXIAS; TAURINE;

EID: 84887605878     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12435     Document Type: Article

References (31)

1. Burright E. N., Clark H. B., Servadio A., Matilla T., Feddersen R. M., Yunis W. S., Duvick L. A., Zoghbi H. Y., and, Orr H. T., (1995) SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 82, 937-948.
2. Clark H. B., Burright E. N., Yunis W. S., Larson S., Wilcox C., Hartman B., Matilla A., Zoghbi H. Y., and, Orr H. T., (1997) Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J. Neurosci. 17, 7385-7395.
3. Cudalbu C., McLin V. A., Lei H., Duarte J. M. N., Rougemont A.-L., Oldani G., Terraz S., Toso C., and, Gruetter R., (2013) The C57BL/6J mouse exhibits sporadic congenital portosystemic shunts. PLoS ONE 8, e69782.
4. Eder K., Kish S. J., Kirchgessner M., and, Ross B. M., (1998) Brain phospholipids and fatty acids in Friedreich's ataxia and spinocerebellar atrophy type-1. Mov. Disord. 13, 813-819.
5. Garwood M., and, DelaBarre L., (2001) The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. J. Magn. Reson. 153, 155-177.
6. Gruetter R., and, Tkáč I., (2000) Field mapping without reference scan using asymmetric echo-planar techniques. Magn. Reson. Med. 43, 319-323.
7. Hennig J., Nauerth A., and, Friedburg H., (1986) RARE imaging: a fast imaging method for clinical MR. Magn. Reson. Med. 3, 823-833.
8. Klockgether T., (2011) Update on degenerative ataxias. Curr. Opin. Neurol. 24, 339-345.
9. Klockgether T., and, Paulson H., (2011) Milestones in ataxia. Mov. Disord. 26, 1134-1141.
10. 2 relaxation study of water, N-acetylaspartate, and creatine in human brain using Hahn and Carr-Purcell spin echoes at 4T and 7T. Magn. Reson. Med. 47, 629-633.
11. Miller T. J., Hanson R. D., and, Yancey P. H., (2000) Developmental changes in organic osmolytes in prenatal and postnatal rat tissues. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. 125, 45-56.
12. Mountford C. E., Stanwell P., Lin A., Ramadan S., and, Ross B., (2010) Neurospectroscopy: the past, present and future. Chem. Rev. 110, 3060-3086.
13. Ottersen O. P., Madsen S., Storm-Mathisen J., Somogyi P., Scopsi L., and, Larsson L. I., (1988) Immunocytochemical evidence suggests that taurine is colocalized with GABA in the Purkinje cell terminals, but that the stellate cell terminals predominantly contain GABA: a light- and electronmicroscopic study of the rat cerebellum. Exp. Brain Res. 72, 407-416.
14. Öz G,. (2013) MR Spectroscopy in Health and Disease, in Handbook of the Cerebellum and Cerebellar Disorders (, Manto M., Gruol D. L., Schmahmann J. D., Koibuchi N.and Rossi F., and, Rossi F., eds), Vol. 1, pp. 713-733. Springer Dordrecht, Netherlands.
15. Öz G., Hutter D., Tkáč I., Clark H. B., Gross M. D., Jiang H., Eberly L. E., Bushara K. O., and, Gomez C. M., (2010a) Neurochemical alterations in spinocerebellar ataxia type 1 and their correlations with clinical status. Mov. Disord. 25, 1253-1261.
16. Öz G., Nelson C. D., Koski D. M., et al,. (2010b) Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J. Neurosci. 30, 3831-3838.
17. Öz G., Vollmers M. L., Nelson C. D., Shanley R., Eberly L. E., Orr H. T., and, Clark H. B., (2011) In vivo monitoring of recovery from neurodegeneration in conditional transgenic SCA1 mice. Exp. Neurol. 232, 290-298.
18. Petroff O. A., Pleban L. A., and, Spencer D. D., (1995) Symbiosis between in vivo and in vitro NMR spectroscopy: the creatine, N-acetylaspartate, glutamate, and GABA content of the epileptic human brain. Magn. Reson. Imaging 13, 1197-1211.
19. Provencher S. W., (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn. Reson. Med. 30, 672-679.
20. Provencher S. W,. (2001) LCModel & LCMgui User's Manual.
21. Ross B. M., Eder K., Moszczynska A., et al,. (2000) Abnormal activity of membrane phospholipid synthetic enzymes in the brain of patients with Friedreich's ataxia and spinocerebellar atrophy type-1. Mov. Disord. 15, 294-300.
22. Schöls L., Bauer P., Schmidt T., Schulte T., and, Riess O., (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol. 3, 291-304.
23. Storm-Mathisen J., Danbolt N. C., Rothe F., Torp R., Zhang N., Aas J. E., Kanner B. I., Langmoen I., and, Ottersen O. P., (1992) Ultrastructural immunocytochemical observations on the localization, metabolism and transport of glutamate in normal and ischemic brain tissue. Prog. Brain Res. 94, 225-241.
24. Swanson R. A., Sagar S. M., and, Sharp F. R., (1989) Regional brain glycogen stores and metabolism during complete global ischaemia. Neurol. Res. 11, 24-28.
25. Tkáč I., Zacharoff L., and, Dubinsky J. M,. (2011) Longitudinal study of neurochemical changes in Q140 mouse model of Huntington's disease, in Nineteenth Scientific Meeting of the ISMRM pp. 2288. Montreal, Canada.
26. Watase K., Weeber E. J., Xu B., et al,. (2002) A long CAG repeat in the mouse Sca1 locus replicates SCA1 features and reveals the impact of protein solubility on selective neurodegeneration. Neuron 34, 905-919.
27. Wu J. Y., and, Prentice H., (2010) Role of taurine in the central nervous system. J. Biomed. Sci. 17 (Suppl 1), S1.
28. Wüllner U., Reimold M., Abele M., Burk K., Minnerop M., Dohmen B. M., Machulla H. J., Bares R., and, Klockgether T., (2005) Dopamine transporter positron emission tomography in spinocerebellar ataxias type 1, 2, 3, and 6. Arch. Neurol. 62, 1280-1285.
29. 2 relaxation time of J-coupled cerebral metabolites in rat brain at 9.4 T. NMR Biomed. 21, 396-401.
30. Zoghbi H. Y., and, Orr H. T., (2000) Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23, 217-247.
31. Zu T., Duvick L. A., Kaytor M. D., Berlinger M. S., Zoghbi H. Y., Clark H. B., and, Orr H. T., (2004) Recovery from polyglutamine-induced neurodegeneration in conditional SCA1 transgenic mice. J. Neurosci. 24, 8853-8861.